PaceMate Hits 100,000th Patient Transmission Milestone with Cutting-Edge Ambulatory Remote Monitoring Platform

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Significant Achievement Cements the Company’s Leadership in Cardiac Data Management

SARASOTA, Fla.–(BUSINESS WIRE)–PaceMate®, a market-leading cardiac remote monitoring and cardiac data management platform, announced today the completion of its 100,000th ambulatory patient transmission managed through PaceMateLIVE™. This achievement shows PaceMate as a proven solution with tangible results in real-world applications.

PaceMate leverages advanced algorithms to deliver the only end-to-end solution, merging the entire workflow – from ordering to billing – into a singular, efficient experience. PaceMate automates device ordering, calculates wear time, and automatically scripts reports, minimizing denials and ensuring accurate billing information is processed. With PaceMate, clinicians experience a 50% reduction in time spent on administrative ambulatory-related tasks, transforming more than 150-clicks into a concise 3-click process.*

“This milestone is not just a number – it’s a testament to the trust and reliance placed in us by healthcare providers and their patients across the nation. PaceMate is the universal solution for cardiac data management across the disease spectrum,” said Tripp Higgins, CEO and Co-Founder of PaceMate. “We are proud to offer the only platform that integrates with all major ambulatory patch vendors, granting healthcare providers the freedom to choose and ensuring the best care for their patients,” said Higgins.

PaceMate provides clinicians the flexibility to choose from the top five ambulatory monitoring manufacturers with one single integration for a tailored healthcare solution.

“One of the most valuable aspects of PaceMate is the flexibility it offers in selecting ambulatory vendors that best fit our specific needs, thanks to its comprehensive integrations with all major ambulatory patch vendors,” said Saumil Oza, M.D., FACC, Ascension Medical Group, St. Vincent’s. “This flexibility gives us significant choice and contracting power, which is a critical advantage. PaceMate’s capability to integrate wearable technologies has transformed our operational efficiency, eliminating the need to navigate between multiple platforms. This has been a game-changer for our practice and significantly enhanced patient care.”

This milestone comes after strategic investment by Lead Edge Capital, a growth stage investment firm focused on the internet, software, consumer, and tech-enabled service sectors. PaceMate remains steadfast in its commitment to improving lives and continues to push the boundaries in healthcare technology, making significant strides in cardiac care.

About PaceMate:

PaceMate is a pioneering force in remote cardiac data management. We’re driven by a mission to modernize digital healthcare and envision a future of connected personalized cardiac care. Since 2015, PaceMate has been simplifying and streamlining device clinic operations into one easy-to-use platform. PaceMateLIVE offers the most comprehensive remote cardiac monitoring solution, uniquely pairing device and EHR data to easily prioritize patient care intelligently. Join us at PaceMate.com to see how together, we never miss a beat.

*Warren, Jaime Ed.D, MBA, BHS, CNMT, NCT, FACC, Kennedy, Jenny, MSN, RN, CHFN, NEA-BC, “Streamlining Ambulatory Cardiac Monitoring: A Case Study on PaceMate Remote Monitoring”; MedAxiom, March 2024.

Contacts

Haley Chute

haley.chute@pacemate.com

Staff

Recent Posts

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…

2 hours ago

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…

2 hours ago

SetPoint Medical Raises $140 Million in Private Financing and Expands Leadership Team to Support Commercialization of Rheumatoid Arthritis Therapy

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a company dedicated to developing therapies for people living with chronic…

2 hours ago

SetPoint Medical Raises $140 Million in Private Financing and Expands Leadership Team to Support Commercialization of Rheumatoid Arthritis Therapy

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a company dedicated to developing therapies for people living with chronic…

2 hours ago

Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025

Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC…

2 hours ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”…

2 hours ago